{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:22:08Z","timestamp":1790626928885,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI21\/01639"],"award-info":[{"award-number":["PI21\/01639"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI22\/00155"],"award-info":[{"award-number":["PI22\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"crossref","award":["PI24\/01602"],"award-info":[{"award-number":["PI24\/01602"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN607D 2023\/04"],"award-info":[{"award-number":["IN607D 2023\/04"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["IN607D 2024\/05"],"award-info":[{"award-number":["IN607D 2024\/05"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Duchenne muscular dystrophy (DMD) is a genetic, progressive neuromuscular disease caused by mutations in the dystrophin protein which compromise the integrity of the sarcolemma. Current care of DMD involves both supportive and targeted disease modifying medications. Obestatin, a peptide derived from preproghrelin, is a potential candidate to enhance existing treatments for DMD. This study was conducted to analyse the molecular mechanism by which obestatin acts on myofiber metabolism and muscle restructuring in DMD. Through human and animal models of DMD, we identify the calcium-activated protein phosphatase 3 (PPP3) as key node in obestatin signalling for restoration of muscle homeostasis and activation of membrane repair. In particular, we describe how obestatin signalling recovers muscle function by coordinated activation of the transcription factor EB (TFEB) and the nuclear factor of activated T cell (NFATc1) in which PPP3 is a core component. TFEB dephosphorylation triggers its nuclear translocation and the activation of macroautophagic\/autophagic and mitochondrial biogenesis. NFATc1 promotes the slow myofiber phenotype fibre marker utrophin. Overall, obestatin treatment ameliorates distinctive dystrophic features of DMD, including muscle contractile damage, elevated serum creatine kinase levels, and reduced muscle force. Hence, obestatin represents a promising therapeutic approach for treating DMD, not only as monotherapy but also as part of combinatorial treatment strategies aimed at overcoming the barriers that limit the efficacy of gene or cell therapy.<\/jats:p>","DOI":"10.1186\/s43556-025-00370-8","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:27:51Z","timestamp":1764055671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obestatin treatment links mitochondrial homeostasis and skeletal muscle repair in Duchenne muscle dystrophy"],"prefix":"10.1186","volume":"6","author":[{"given":"Andrea C.","family":"Lodeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Costas-Abalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Cid-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Debasa-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00fal","family":"Leal-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mamchaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xes\u00fas","family":"Casabiell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosal\u00eda","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Relova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ic\u00eda","family":"Santos-Zas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus P.","family":"Cami\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"1","key":"370_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primer. 2021;7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primer"},{"issue":"11","key":"370_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22(11):917\u201334. https:\/\/doi.org\/10.1038\/s41573-023-00775-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"370_CR3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","volume":"33","author":"NE Bengtsson","year":"2025","unstructured":"Bengtsson NE, Tasfaout H, Chamberlain JS. The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy. Mol Ther. 2025;33(5):2035\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.065.","journal-title":"Mol Ther"},{"issue":"6","key":"370_CR4","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","volume":"33","author":"L Torres-Masjoan","year":"2025","unstructured":"Torres-Masjoan L, Aguti S, Zhou H, Muntoni F. Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases. Mol Ther. 2025;33(6):2689\u2013704. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.038.","journal-title":"Mol Ther"},{"issue":"3","key":"370_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","volume":"30","author":"C Mozzetta","year":"2024","unstructured":"Mozzetta C, Sartorelli V, Steinkuhler C, Puri PL. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol Med. 2024;30(3):278\u201394. https:\/\/doi.org\/10.1016\/j.molmed.2024.01.007.","journal-title":"Trends Mol Med"},{"issue":"5","key":"370_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41434-025-00531-y","volume":"35","author":"DC G\u00f3recki","year":"2025","unstructured":"G\u00f3recki DC, Kalinski P, Pomeroy J. Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy? Gene Ther. 2025;35(5):561\u20138. https:\/\/doi.org\/10.1038\/s41434-025-00531-y.","journal-title":"Gene Ther"},{"key":"370_CR7","doi-asserted-by":"publisher","first-page":"689533","DOI":"10.3389\/fcell.2021.689533","volume":"9","author":"S Yao","year":"2021","unstructured":"Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G, et al. Current pharmacological strategies for Duchenne muscular dystrophy. Front Cell Dev Biol. 2021;9:689533. https:\/\/doi.org\/10.3389\/fcell.2021.689533.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"370_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022;21(9):814\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(22)00125-9.","journal-title":"Lancet Neurol"},{"key":"370_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fgene.2018.00114","volume":"9","author":"G Cordova","year":"2018","unstructured":"Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front Genet. 2018;9:114. https:\/\/doi.org\/10.3389\/fgene.2018.00114.","journal-title":"Front Genet"},{"issue":"45","key":"370_CR10","doi-asserted-by":"publisher","first-page":"38379","DOI":"10.1074\/jbc.M112.374926","volume":"287","author":"U Gurriar\u00e1n-Rodr\u00edguez","year":"2012","unstructured":"Gurriar\u00e1n-Rodr\u00edguez U, Santos-Zas I, Al-Massadi O, Mosteiro CS, Beiroa D, Nogueiras R, et al. The obestatin\/GPR39 system is up-regulated by muscle injury and functions as an autocrine regenerative system. J Biol Chem. 2012;287(45):38379\u201389. https:\/\/doi.org\/10.1074\/jbc.M112.374926.","journal-title":"J Biol Chem"},{"issue":"6","key":"370_CR11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/mt.2015.40","volume":"23","author":"U Gurriar\u00e1n-Rodr\u00edguez","year":"2015","unstructured":"Gurriar\u00e1n-Rodr\u00edguez U, Santos-Zas I, Gonz\u00e1lez-S\u00e1nchez J, Beiroa D, Moresi V, Mosteiro CS, et al. Action of obestatin in skeletal muscle repair: stem cell expansion, muscle growth, and microenvironment remodeling. Mol Ther. 2015;23(6):1003\u201321. https:\/\/doi.org\/10.1038\/mt.2015.40.","journal-title":"Mol Ther"},{"issue":"3","key":"370_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00018-015-1994-z","volume":"73","author":"I Santos-Zas","year":"2016","unstructured":"Santos-Zas I, Gurriar\u00e1n-Rodr\u00edguez U, Cid-D\u00edaz T, Cid-Diaz T, Figueroa G, Gonzalez-Sanchez J, et al. \u0392-arrestin scaffolds and signaling elements essential for the obestatin\/GPR39 system that determine the myogenic program in human myoblast cells. Cell Mol Life Sci. 2016;73(3):617\u201335. https:\/\/doi.org\/10.1007\/s00018-015-1994-z.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"370_CR13","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1038\/s41598-017-02337-4","volume":"7","author":"I Santos-Zas","year":"2017","unstructured":"Santos-Zas I, Cid-D\u00edaz T, Gonz\u00e1lez-S\u00e1nchez J, Gurriaran-Rodriguez U, Mosteiro CS, Porteiro B, et al. Obestatin controls skeletal muscle fiber-type determination. Sci Rep. 2017;7(1):2137. https:\/\/doi.org\/10.1038\/s41598-017-02337-4.","journal-title":"Sci Rep"},{"issue":"6","key":"370_CR14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jcsm.12222","volume":"8","author":"T Cid-D\u00edaz","year":"2017","unstructured":"Cid-D\u00edaz T, Santos-Zas I, Gonz\u00e1lez-S\u00e1nchez J, Gurriaran-Rodriguez U, Mosteiro CS, Casabiell X, et al. Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in glucocorticoid-induced muscle cell atrophy. J Cachexia Sarcopenia Muscle. 2017;8(6):974\u201390. https:\/\/doi.org\/10.1002\/jcsm.12222.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"370_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jcsm.12677","volume":"12","author":"T Cid-D\u00edaz","year":"2021","unstructured":"Cid-D\u00edaz T, Leal-L\u00f3pez S, Fern\u00e1ndez-Barreiro F, Gonzalez-Sanchez J, Santos-Zas I, Andrade-Bulos LJ, et al. Obestatin signalling counteracts glucocorticoid-induced skeletal muscle atrophy via NEDD4\/KLF15 axis. J Cachexia Sarcopenia Muscle. 2021;12(2):493\u2013505. https:\/\/doi.org\/10.1002\/jcsm.12677.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"370_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/jcsm.12338","volume":"9","author":"J Gonz\u00e1lez-S\u00e1nchez","year":"2018","unstructured":"Gonz\u00e1lez-S\u00e1nchez J, S\u00e1nchez-Temprano A, Cid-D\u00edaz T, Pabst-Fernandez R, Mosteiro CS, Gallego R, et al. Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment. J Cachexia Sarcopenia Muscle. 2018;9(6):1063\u201378. https:\/\/doi.org\/10.1002\/jcsm.12338.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"370_CR17","doi-asserted-by":"publisher","first-page":"112434","DOI":"10.1016\/j.celrep.2023.112434","volume":"42","author":"T Yasuda","year":"2023","unstructured":"Yasuda T, Ishihara T, Ichimura A, Ishihara N. Mitochondrial dynamics define muscle fiber type by modulating cellular metabolic pathways. Cell Rep. 2023;42(5):112434. https:\/\/doi.org\/10.1016\/j.celrep.2023.112434.","journal-title":"Cell Rep"},{"issue":"1","key":"370_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41392-023-01547-9","volume":"8","author":"W Chen","year":"2023","unstructured":"Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023;8(1):333. https:\/\/doi.org\/10.1038\/s41392-023-01547-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"370_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s43556-025-00284-5","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Zhou X, Lu T. Role of mitochondria in physiological activities, diseases, and therapy. Mol Biomed. 2025;6(1):42. https:\/\/doi.org\/10.1186\/s43556-025-00284-5.","journal-title":"Mol Biomed"},{"issue":"13","key":"370_CR20","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.1073\/pnas.0932671100","volume":"100","author":"JV Chakkalakal","year":"2003","unstructured":"Chakkalakal JV, Stocksley MA, Harrison M-A, Angus LM, Deschenes-Furry J, St-Pierre S, et al. Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin\/NFAT signaling. Proc Natl Acad Sci USA. 2003;100(13):7791\u20136. https:\/\/doi.org\/10.1073\/pnas.0932671100.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"370_CR21","doi-asserted-by":"publisher","first-page":"a035436","DOI":"10.1101\/cshperspect.a035436","volume":"12","author":"J Roy","year":"2020","unstructured":"Roy J, Cyert MS. Identifying new substrates and functions for an old enzyme: calcineurin. Cold Spring Harb Perspect Biol. 2020;12(3):a035436. https:\/\/doi.org\/10.1101\/cshperspect.a035436.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"370_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ncb3114","volume":"17","author":"DL Medina","year":"2015","unstructured":"Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and \u200bTFEB. Nat Cell Biol. 2015;17(3):288\u201399. https:\/\/doi.org\/10.1038\/ncb3114.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"370_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCRESAHA.119.316007","volume":"127","author":"B Pan","year":"2020","unstructured":"Pan B, Li J, Parajuli N, Tian Z, Wu P, Lewno MT, et al. The calcineurin-TFEB-p62 pathway mediates the activation of cardiac macroautophagy by proteasomal malfunction. Circ Res. 2020;127(4):502\u201318. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316007.","journal-title":"Circ Res"},{"issue":"7","key":"370_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s0092-8674(00)80880-6","volume":"101","author":"EN Olson","year":"2000","unstructured":"Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell. 2000;101(7):689\u201392. https:\/\/doi.org\/10.1016\/s0092-8674(00)80880-6.","journal-title":"Cell"},{"issue":"6","key":"370_CR25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4161\/auto.19653","volume":"8","author":"JA Martina","year":"2012","unstructured":"Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903\u201314. https:\/\/doi.org\/10.4161\/auto.19653.","journal-title":"Autophagy"},{"issue":"228","key":"370_CR26","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2002790","volume":"5","author":"A Roczniak-Ferguson","year":"2012","unstructured":"Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42. https:\/\/doi.org\/10.1126\/scisignal.2002790.","journal-title":"Sci Signal"},{"issue":"5","key":"370_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/emboj.2012.32","volume":"31","author":"C Settembre","year":"2012","unstructured":"Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31(5):1095\u2013108. https:\/\/doi.org\/10.1038\/emboj.2012.32.","journal-title":"EMBO J"},{"issue":"1","key":"370_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cmet.2016.11.003","volume":"25","author":"G Mansueto","year":"2017","unstructured":"Mansueto G, Armani A, Viscomi C, D\u2019Orsi L, De Cegli R, Polishchuk EV, et al. Transcription factor EB controls metabolic flexibility during exercise. Cell Metab. 2017;25(1):182\u201396. https:\/\/doi.org\/10.1016\/j.cmet.2016.11.003.","journal-title":"Cell Metab"},{"issue":"32","key":"370_CR29","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1073\/pnas.0812911106","volume":"106","author":"E Calabria","year":"2009","unstructured":"Calabria E, Ciciliot S, Moretti I, Garcia M, Picard A, Dyar KA, et al. NFAT isoforms control activity-dependent muscle fiber type specification. Proc Natl Acad Sci USA. 2009;106(32):13335\u201340. https:\/\/doi.org\/10.1073\/pnas.0812911106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"370_CR30","doi-asserted-by":"publisher","first-page":"10590","DOI":"10.1073\/pnas.0308035101","volume":"101","author":"KJA McCullagh","year":"2004","unstructured":"McCullagh KJA, Calabria E, Pallafacchina G, Ciciliot S, Serrano AL, Argenti C, et al. NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myosin switching. Proc Natl Acad Sci USA. 2004;101(29):10590\u20135. https:\/\/doi.org\/10.1073\/pnas.0308035101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"370_CR31","doi-asserted-by":"publisher","first-page":"C908","DOI":"10.1152\/ajpcell.00196.2005","volume":"289","author":"LM Angus","year":"2005","unstructured":"Angus LM, Chakkalakal JV, M\u00e9jat A, Eibl JK, Belanger G, Megeney LA, et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. Am J Physiol Cell Physiol. 2005;289(4):C908-917. https:\/\/doi.org\/10.1152\/ajpcell.00196.2005.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"370_CR32","doi-asserted-by":"publisher","first-page":"e30063","DOI":"10.1371\/journal.pone.0030063","volume":"7","author":"JT Selsby","year":"2012","unstructured":"Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL. Rescue of dystrophic skeletal muscle by PGC-1\u03b1 involves a fast to slow fiber type shift in the mdx mouse. PLoS ONE. 2012;7(1):e30063. https:\/\/doi.org\/10.1371\/journal.pone.0030063.","journal-title":"PLoS ONE"},{"issue":"1","key":"370_CR33","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1152\/ajpregu.00221.2012","volume":"305","author":"K Hollinger","year":"2013","unstructured":"Hollinger K, Gardan-Salmon D, Santana C, Santana C, Rice D, Snella E, et al. Rescue of dystrophic skeletal muscle by PGC-1\u03b1 involves restored expression of dystrophin-associated protein complex components and satellite cell signaling. Am J Physiol Regul Integr Comp Physiol. 2013;305(1):R13-23. https:\/\/doi.org\/10.1152\/ajpregu.00221.2012.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"370_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","volume":"22","author":"K Sengupta","year":"2020","unstructured":"Sengupta K, Mishra MK, Loro E, Spencer MJ, Pyle AD, Khurana TS. Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells. Mol Ther Nucleic Acids. 2020;22:500\u20139. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.031.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"8048","key":"370_CR35","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41586-024-08310-2","volume":"637","author":"L Wan","year":"2025","unstructured":"Wan L, Ge X, Xu Q, Huang G, Yang T, Campbell KP, et al. Structure and assembly of the dystrophin glycoprotein complex. Nature. 2025;637(8048):1252\u201360. https:\/\/doi.org\/10.1038\/s41586-024-08310-2.","journal-title":"Nature"},{"issue":"5","key":"370_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","volume":"25","author":"JR Chamberlain","year":"2017","unstructured":"Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther. 2017;25(5):1125\u201331. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.019.","journal-title":"Mol Ther"},{"issue":"11","key":"370_CR37","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/j.ymthe.2021.04.002","volume":"29","author":"E Choi","year":"2021","unstructured":"Choi E, Koo T. Crispr technologies for the treatment of Duchenne muscular dystrophy. Mol Ther. 2021;29(11):3179\u201391. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.002.","journal-title":"Mol Ther"},{"key":"370_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","volume":"70","author":"Y-L Min","year":"2019","unstructured":"Min Y-L, Bassel-Duby R, Olson EN. Crispr correction of Duchenne muscular dystrophy. Annu Rev Med. 2019;70:239\u201355. https:\/\/doi.org\/10.1146\/annurev-med-081117-010451.","journal-title":"Annu Rev Med"},{"issue":"1","key":"370_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31(1):332\u201341. https:\/\/doi.org\/10.1038\/s41591-024-03304-z.","journal-title":"Nat Med"},{"issue":"10","key":"370_CR40","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ymthe.2017.06.022","volume":"25","author":"I Santos-Zas","year":"2017","unstructured":"Santos-Zas I, Negroni E, Mamchaoui K, Mosteiro CS, Gallego R, Butler-Browne GS, et al. Obestatin increases the regenerative capacity of human myoblasts transplanted intramuscularly in an immunodeficient mouse model. Mol Ther. 2017;25(10):2345\u201359. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.022.","journal-title":"Mol Ther"},{"issue":"8","key":"370_CR41","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/mt.2013.121","volume":"21","author":"M Le Hir","year":"2013","unstructured":"Le Hir M, Goyenvalle A, Peccate C, Precigout G, Davies KE, Voit T, et al. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol Ther. 2013;21(8):1551\u20138. https:\/\/doi.org\/10.1038\/mt.2013.121.","journal-title":"Mol Ther"},{"issue":"16","key":"370_CR42","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/hmg\/ddw201","volume":"25","author":"C Peccate","year":"2016","unstructured":"Peccate C, Mollard A, Le Hir M, Julien L, McClorey G, Jarmin S, et al. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet. 2016;25(16):3555\u201363. https:\/\/doi.org\/10.1093\/hmg\/ddw201.","journal-title":"Hum Mol Genet"},{"key":"370_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle. 2011;1:34. https:\/\/doi.org\/10.1186\/2044-5040-1-34.","journal-title":"Skelet Muscle"},{"issue":"1","key":"370_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13395-016-0115-5","volume":"6","author":"M Thorley","year":"2016","unstructured":"Thorley M, Duguez S, Mazza EMC, Valsoni S, Bigot A, Mamchaoui K, et al. Skeletal muscle characteristics are preserved in hTERT\/cdk4 human myogenic cell lines. Skelet Muscle. 2016;6(1):43. https:\/\/doi.org\/10.1186\/s13395-016-0115-5.","journal-title":"Skelet Muscle"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00370-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00370-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:02:06Z","timestamp":1764100926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00370-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00370-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols for animal experiments were approved by the Bioethics Committee at the University of Santiago de Compostela according to the guidelines of the Spanish Royal Decree 53\/2013, Directive 2010\/63\/EU, and FELASA Guidelines (Approval n\u00ba. 15010\/17\/005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}